These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31831554)

  • 61. Olaparib.
    Bochum S; Berger S; Martens UM
    Recent Results Cancer Res; 2018; 211():217-233. PubMed ID: 30069770
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CRISPR screens identify a novel combination treatment targeting BCL-X
    Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY
    Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
    Min A; Im SA; Yoon YK; Song SH; Nam HJ; Hur HS; Kim HP; Lee KH; Han SW; Oh DY; Kim TY; O'Connor MJ; Kim WH; Bang YJ
    Mol Cancer Ther; 2013 Jun; 12(6):865-77. PubMed ID: 23512992
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
    Andreidesz K; Koszegi B; Kovacs D; Bagone Vantus V; Gallyas F; Kovacs K
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669671
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
    Pai Bellare G; Saha B; Patro BS
    Br J Cancer; 2021 Mar; 124(7):1260-1274. PubMed ID: 33473172
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells.
    Qin C; Ji Z; Zhai E; Xu K; Zhang Y; Li Q; Jing H; Wang X; Song X
    Cell Death Dis; 2022 May; 13(5):505. PubMed ID: 35643812
    [TBL] [Abstract][Full Text] [Related]  

  • 76. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
    Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    Suzuki Y; Wenwen W; Ohta T; Hayashi SI
    Breast Cancer; 2022 Jan; 29(1):77-91. PubMed ID: 34346034
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
    Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN
    Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
    Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.